Coming May 2025
Get Early Access
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
From TechCrunch
By Marina Temkin
May 15, 2024
For years, Sammy Faycurry has been hearing from his dietician mom and sister about how poorly many Americans eat and their struggles with delivering nutritional counseling.
Although nearly half of all adults in the country are affected by chronic conditions linked to unhealthy diets, health plans have a limited number of in-network registered dieticians.
Faycurry decided to build a platform that would empower RDs, like his mom and sister, to start their own practices while being covered by insurance.
He began working on Fay, a startup that connects RDs with insurances and patients, when he was an MBA student at Harvard Business School in 2021. About a year into his effort, which Faycurry initially bootstrapped, he asked Mark Stefanski to join him as a CTO.
On Wednesday, Fay emerged from stealth after quietly raising $25 million from General Catalyst and Forerunner Ventures, with participation from 1984 and the founders of Grow Therapy and Maven Clinic.
Fay offers RDs a franchise model that has gained popularity among certain types of healthcare providers in recent years. The so-called business-in-box gives practitioners, such as dietitians and therapists, the tools for running their practices, including filing claims with insurance, receiving payments and being matched with patients.
“Insurance companies love it because their patients are getting healthier. And the dietitians love it because they can make almost five to eight times more money as independent practitioners with our platform than they earn in a hospital,” Faycurry told TechCrunch.
Other startups that have implemented this business model include Grow, a network for therapists that last month raised an $88 million Series C led by Sequoia and Nourish, which, just like Fay, matches RDs with patients. Nourish closed its $35 million Series A in March in a round led by Index Ventures.
Fay currently has 1,000 RDs on its platform and allows people covered by Anthem, United Healthcare, Aetna CVS, Blue Cross, Cigna, Optum, Humana, and other insurance providers to use their services weekly or bi-weekly for a price of a regular co-payment.
“Payers and employers’ costs have been skyrocketing for a long time. Everyone’s saying diet, diet, diet, and then no one has been doing anything about it,” Faycurry said.
Curiously, many of Fay’s patients are people who take Ozempic and other GLP-1 medicines, which are currently being touted as miracle weight loss drugs. That’s because doctors who prescribe these medications require patients to see a dietician so they learn healthy habits. “We’ve seen people who lost 25 pounds, but they still have high cholesterol because they’re having a slice of bacon with every meal,” Faycurry said.
Nicole Johnson, a partner at Forerunner Ventures, said that her firm was impressed with Fay’s execution. “They got off to a really quick start and grew revenues at an incredibly fast pace while burning very little capital.” And Fay has big plans for future expansion into meal delivery, too, Johnson said.
UK founders grow frustrated over dearth of funding: ‘the problem is getting worse’
According to Dealroom data cited by the Financial Times, British start-ups raised just £16.2 billion last year, far less than the more than £65 billion raised by their counterparts in Silicon Valley during the same period. In fact, the U.S. appears to be pulling further ahead each year. In 2024, 57% of global venture capital funding went to U.S. startups — the first time that share has exceeded 50% in over a decade, per Dealroom. This widening gap is part of a years-long trend that U.K. founder
Apr 13, 2025
OpenAI co-founder Ilya Sutskever’s Safe Superintelligence reportedly valued at $32B
Safe Superintelligence (SSI), the AI startup led by OpenAI’s co-founder and former chief scientist Ilya Sutskever, has raised an additional $2 billion in funding at a $32 billion valuation, according to the Financial Times. The startup had already raised $1 billion, and there were reports that an additional $1 billion round was in the works. SSI did not comment on the new funding, which was reportedly led by Greenoaks. Sutskever left OpenAI in May 2024 after he appeared to play a role in an ult
Apr 12, 2025
Cofertility’s radical model for women: Freeze your eggs for free by donating half of them
In recent years, focus on career and delayed marriage age is driving some women to consider preserving their fertility through egg freezing. But the steep cost of the procedure, estimated at $10,000 to $15,000 per attempt, means many women can’t afford it during their most fertile years: 20s and early 30s. Cofertility, a startup founded by former Uber executive Lauren Makler and health tech angel investor Halle Tecco, offers women no-cost egg freezing in exchange for donating half the retrieved
Apr 12, 2025